EU and US could reach trade deal this weekend - Reuters
DarioHealth Corp. (NASDAQ:DRIO), currently trading at $0.69 per share and down over 60% in the past year, has announced amendments to its preferred stock terms, extending the mandatory conversion period and implementing a new dividend policy. On Monday, the company filed updated certificates of designation for its Series C, Series C-1, and Series C-2 Preferred Stock with the Delaware Secretary of State. According to InvestingPro analysis, the company is currently burning through cash rapidly, which may explain these strategic financial moves.
The amendments extend the mandatory conversion period for these preferred stocks from 15 to 24 months from the original issue date. Additionally, DarioHealth introduced a dividend policy where holders of the preferred stocks will receive a dividend equal to 15% of the Common Stock shares issuable upon conversion for each full quarter anniversary post-filing. While the company is making these changes to its preferred stock structure, InvestingPro data shows the company does not currently pay dividends to common shareholders and operates with a moderate debt level.
This strategic move did not involve the issuance or sale of additional securities. The company’s decision to amend the certificates of designation aims to adjust the terms of the preferred stock without altering the current number of shares.
DarioHealth, a Delaware-incorporated company with a market capitalization of approximately $29 million, specializes in surgical and medical instruments and apparatus. It operates under the name 08 Industrial Applications and Services and is headquartered in New York, NY. Despite challenging market conditions, the company has achieved notable revenue growth of 47% in the last twelve months. Get deeper insights into DarioHealth’s financial health and growth prospects with InvestingPro’s comprehensive research report, part of its coverage of over 1,400 US stocks.
The full text of the amended certificates can be found in the exhibits attached to the Form 8-K filed with the SEC. This report is based on a press release statement from DarioHealth Corp.
In other recent news, DarioHealth Corp reported its first-quarter 2025 earnings, revealing an earnings per share (EPS) of $0.14, which exceeded the forecasted loss of $0.10. However, the company’s revenue of $6.75 million fell short of the expected $7.47 million. Despite the revenue miss, DarioHealth noted a 17% year-over-year increase in revenue and maintained strong gross margins at 81% for its core business. Stifel analysts have adjusted their price target for DarioHealth, lowering it from $2.00 to $1.50 while maintaining a Buy rating. The adjustment follows the company’s performance and expectations of future contract awards from the second half of 2025 into 2026. Management aims to reach free cash flow breakeven by early 2026, with Stifel projecting this milestone in late 2026 or early 2027. DarioHealth is also focusing on expanding its client base and has signed 14 new clients in the first quarter. The company continues to leverage its platform to support five chronic conditions, aiming for operational cash flow breakeven by the end of 2025 or early 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.